Categories: BodyInterestManufacturingPlatform
We develop bispecific antibodies that exploit the potential of the natural immune system. Our Amplify•R platform amplifies and redirects endogenous cytokine signaling instead of recombinant cytokines. We avoid issues such as systemic toxicity, immunogenicity and manufacturing concerns.
Investors 2
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.02.2025 | Seed | $12M | - |
Mentions in press and media 4
| Date | Title | Description |
| 28.02.2025 | Reverb Therapeutics: A New Dawn in Cytokine Therapy | In the world of biotechnology, innovation is the lifeblood. Reverb Therapeutics, a Vancouver-based company, is making waves with its recent $12 million seed funding. This investment, led by Amplitude Ventures, signals a promising shift in h... |
| 24.02.2025 | Reverb Therapeutics: $12 Million (Seed) Raised To Utilize Cytokine Signaling For Treating Diseases | Reverb Therapeutics, a leader in harnessing the natural immune system and cytokine signaling to treat life-threatening diseases, announced it has closed a $12 million financing led by founding investor Amplitude Ventures. And other particip... |
| 19.02.2025 | Reverb Therapeutics Raises USD $12M in Seed Financing | Reverb Therapeutics, a Vancouver, BC, Canada-based a leader in harnessing the natural immune system and cytokine signaling to treat life-threatening diseases, raised USD $21M in Seed funding.
The round was led by Amplitude Ventures with par... |
| - | Reverb Therapeutics | “Home | Reverb Therapeutics” |
Reviews 0
